Skip to main content

#USA, #Oregon: State ends year with highest #pertussis case count since 1950

As Oregon sweeps past the 1,100 cases mark, health officials remind everyone that vaccination against whooping cough is best way to prevent transmission

PORTLAND, Ore.—Oregon swept past the 1,100 mark for the number of pertussis cases it’s seen during 2024, beating its 2012 record of 910 cases in a single year—and making the need for people to stay up to date with their vaccinations all the more urgent.

As of Monday, Dec. 30, Oregon Health Authority registered 1,105 cases of pertussis—also known as whooping cough—during 2024. There were 44 outbreaks, although the majority of cases were sporadic individual or household-related cases and not associated with outbreaks. The 2024 count represents the highest number of pertussis cases reported in Oregon in a single year since 1950, when 1,420 cases were reported.

Since 2003, eight Oregonians with pertussis have died. Five were younger than 4 months old, and there have been three deaths in adults – one in 2023 and two in 2024.

While Oregon didn’t beat its 74-year record for most cases in a year, 1,105 is still an extremely high number for a vaccine-preventable disease, said Paul Cieslak, M.D., medical director for communicable diseases and immunizations at OHA’s Public Health Division. It’s also a stark reminder of how quickly the bacterial infection can spread and cause illness, particularly among people who are under- or unvaccinated.

“The pertussis vaccine is a public health success story in terms of its effectiveness in reducing severe illness and deaths from the disease—particularly among infants,” Cieslak said.

According to data from the epidemiologists in Oregon Public Health Division’s Acute and Communicable Disease Prevention Section, the median age of the 2024 cases is 12; 7.2% of cases are less than a year old, 80% are 18 or younger and 50% are female. About half of the cases are up to date with pertussis vaccines.

Lane County has reported the highest number of pertussis cases this year with 315. Rounding out the top five counties are Multnomah, 235 cases; Clackamas, 135; Washington, 119; and Marion, 75.

Pertussis case counts vary considerably from year to year, routinely reaching triple digits. However, during the COVID-19 pandemic, restrictions such as masking requirements and school closures were in effect, which kept annual case counts low, Cieslak said. Vaccination rates also slipped.

“People were less motivated to get vaccinated against pertussis when there was less concern they would be exposed to the infection in the first place,” he said.

But with pertussis activity so high this year, there are more opportunities for people to be exposed, Cieslak noted. Those who are unvaccinated or too young to be vaccinated, such as infants, are at the highest risk from infection, with babies most likely to be hospitalized with pertussis.

But there are ways to protect vulnerable individuals. Pregnant people can protect their young babies by getting the Tdap vaccine—which protects against tetanus, diphtheria and pertussis—at 27–36 weeks’ gestation. Mothers will make antibodies and pass them to their babies across the placenta, protecting them from the moment of birth. It is recommended during each pregnancy.

“In recent years, about two-thirds of pregnant Oregonians have been getting vaccinated during pregnancy,” Cieslak said. “However, only 11 of the mothers of the 80 infant cases this year had documentation of having gotten the recommended shot.”

Vaccination against pertussis is routinely recommended for infants, children, adolescents and adults. Children should receive the DTaP vaccine against diphtheria, tetanus and pertussis at 2, 4, 6 and 15 to 18 months old, and again at age 4 to kindergarten age. All persons 10 years old and older should receive a single dose of Tdap.

“Additionally, when pertussis strikes a household in which an infant or pregnant person lives, we recommend all members of the household receive a course of antibiotics effective against Bordetella pertussis—typically, a five-day course of azithromycin,” Cieslak said.

Source: Department of Health, https://content.govdelivery.com/accounts/ORHA/bulletins/3c9f333

______

Comments

Popular posts from this blog

#Neuroinvasive #Oropouche virus in a patient with #HIV from extra-Amazonian #Brazil

{Excerpt} A novel reassortant Oropouche virus (OROV) lineage (with medium [M], large [L], and small [S] RNA segments : M1L2S2) has driven Brazil's largest and most geographically widespread OROV epidemic , expanding beyond the endemic Amazon basin to establish local transmission across multiple Brazilian states and other previously unaffected Latin American countries . The rapid spread of this lineage underscores its evolutionary potential and reinforces its significance as a public health threat .1 Similar to chikungunya and Zika viruses, expanding arboviruses can exhibit unexpected clinical and epidemiological shifts , including vertical transmissions , neuroinvasive effects, and potentially fatal outcomes.2–4 Although OROV typically causes self-limited febrile illness, accumulating clinical and experimental evidence suggests neurotropic potential .5 This Correspondence describes the first confirmed case of neuroinvasive OROV infection caused by the emergent M1L2S2 lineage in ext...

No evidence of immune #exhaustion after repeated #SARS-CoV-2 #vaccination in vulnerable and healthy populations

Abstract Frequent SARS-CoV-2 vaccination in vulnerable populations has raised concerns that this may contribute to T cell exhaustion , which could negatively affect the quality of immune protection. Herein, we examined the impact of repeated SARS-CoV-2 vaccination on T cell phenotypic and functional exhaustion in frail older adults in long-term care (n = 23), individuals on immunosuppressive drugs (n = 10), and healthy adults (n = 43), in Canada . Spike-specific CD4+ and CD8+ T cell levels did not decline in any cohort following repeated SARS-CoV-2 vaccination, nor did the expression of exhaustion markers on spike-specific or total T cells increase. T cell production of multiple cytokines (i.e. polyfunctionality) in response to the spike protein of SARS-CoV-2 did not decline in any cohort following repeated vaccination. None of the cohorts displayed elevated levels of terminally differentiated T cells following multiple SARS-CoV-2 vaccinations. Thus, repeated SARS-CoV-2 vaccination was...

Chimeric #hemagglutinin and #M2 #mRNA #vaccine for broad #influenza subtype protection

Abstract Since multiple and unpredicted influenza viruses cause seasonal epidemics and even high-risk pandemics , developing a universal influenza vaccine is essential to provide broad protection against various influenza subtypes. Combined with the mRNA lipid nanoparticle-encapsulated (mRNA-LNP) vaccine platform and chimeric immunogen strategy , we developed a novel cocktail mRNA vaccine encoding chimeric HAs (cH5/1-BV, cH7/3) and intact M2 (termed Fluaxe), which confers broad protection against major circulating IAVs and IBVs , as well as highly pathogenic avian influenza . Two-dose intramuscular immunization of Fluaxe in mice elicited cross-reactive neutralizing antibodies , T cell responses, and long-lived immunity, resulting in robust protection against multiple lethal influenza virus infections and severe acute lung injuries . In particular, intramuscular administration stimulated systemic immunity together with a prominent lung tropism of memory cells . Moreover, Fluaxe immuniza...